Search Results - "Tsimafeyeu, Ilya"

Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression by Tsimafeyeu, Ilya

“…The treatment landscape for metastatic renal cell carcinoma (RCC) has advanced significantly with first-line immunotargeted therapy combinations. However, no…”
Get full text

Management of non–clear cell renal cell carcinoma: Current approaches by Tsimafeyeu, Ilya, M.D

“…Abstract Non–clear cell renal cell carcinoma includes several histological variants. Tumor biology has significant effect on the duration of the disease…”
Get full text

Immunotherapy in cancer patients with chronic hepatitis C viral infection by Zakurdaeva, Kristina, Tsimafeyeu, Ilya

“…Disease management in challenging patient population with cancer and concomitant serious conditions presents an unmet clinical need. The major gap is the lack…”
Get full text

Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study by Tsimafeyeu, Ilya, Imyanitov, Evgeny, Zavalishina, Larisa, Raskin, Grigory, Povilaitite, Patrisia, Savelov, Nikita, Kharitonova, Ekaterina, Rumyantsev, Alexey, Pugach, Inna, Andreeva, Yulia, Petrov, Alexey, Frank, Georgy, Tjulandin, Sergei

“…The goal of the CLOVER study was to perform a pairwise comparison of four tests based on the same patient population with non-small cell lung cancer (NSCLC):…”
Get full text

Challenges to effective cancer control in China, India, and Russia by Goss, Paul E, Prof, Strasser-Weippl, Kathrin, MD, Lee-Bychkovsky, Brittany L, MD, Fan, Lei, MD, Li, Junjie, MD, Chavarri-Guerra, Yanin, MD, Liedke, Pedro E R, MD, Pramesh, C S, Prof, Badovinac-Crnjevic, Tanja, MD, Sheikine, Yuri, MD, Chen, Zhu, Prof, Qiao, You-lin, Prof, Shao, Zhiming, MD, Wu, Yi-Long, Prof, Fan, Daiming, Prof, Chow, Louis W C, Prof, Wang, Jun, PhD, Zhang, Qiong, PhD, Yu, Shiying, Prof, Shen, Gordon, SM, He, Jie, MD, Purushotham, Arnie, Prof, Sullivan, Richard, Prof, Badwe, Rajendra, MS, Banavali, Shripad D, Prof, Nair, Reena, MD, Kumar, Lalit, Prof, Parikh, Purvish, Prof, Subramanian, Somasundarum, Prof, Chaturvedi, Pankaj, Prof, Iyer, Subramania, Prof, Shastri, Surendra Srinivas, Prof, Digumarti, Raghunadhrao, Prof, Soto-Perez-de-Celis, Enrique, MD, Adilbay, Dauren, PhD, Semiglazov, Vladimir, Prof, Orlov, Sergey, Prof, Kaidarova, Dilyara, Prof, Tsimafeyeu, Ilya, MD, Tatishchev, Sergei, MD, Danishevskiy, Kirill D, Prof, Hurlbert, Marc, PhD, Vail, Caroline, BS, St Louis, Jessica, BA, Chan, Arlene, Prof

“…Summary Cancer is one of the major non-communicable diseases posing a threat to world health. Unfortunately, improvements in socioeconomic conditions are…”
Get full text

Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1 by Imyanitov, Evgeny N., Ivantsov, Alexandr O., Tsimafeyeu, Ilya V.

“…Comprehensive molecular testing plays a critical role in the choice of treatment for non-small lung cell cancer (NSCLC). The analysis of druggable alterations…”
Get full text

Intrapleural nivolumab in cancer patients with pleural effusion by Tsimafeyeu, Ilya, Goutnik, Vadim, Shrainer, Igor, Kosyrev, Vladislav, Bondarenko, Anastasia, Utyashev, Igor

“…We assessed the preliminary efficacy and toxicity of intrapleural instillation of nivolumab in patients with large pleural effusion. Patients with metastatic…”
Get full text

Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection by Tsimafeyeu, Ilya, Gafanov, Rustem, Protsenko, Svetlana, Semenova, Anna, Oganesyan, Ani, Nurgaliyev, Nurzhan, Krasny, Sergei, Bondarenko, Anastasia, Safina, Sufia, Zakurdaeva, Kristina

“…Background Hepatitis C virus (HCV) interferes with activation of innate and adaptive immune responses. Theoretically, the efficacy and toxicity of immune…”
Get full text

Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study by Dengina, Natalia, Mitin, Timur, Gamayunov, Sergey, Safina, Sufia, Kreinina, Yuliya, Tsimafeyeu, Ilya

“…BackgroundTyrosine kinase inhibitors (TKIs) and checkpoint inhibitors have been established as effective treatment for metastatic renal cell carcinoma (mRCC),…”
Get full text

Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies by Tsimafeyeu, Ilya, Volkova, Maria, Alekseeva, Galina, Berkut, Maria, Nosov, Alexander, Myslevtsev, Igor, Andrianov, Andrey, Semenov, Andrey, Borisov, Pavel, Zukov, Ruslan, Goutnik, Vadim, Savchuk, Sergey, Dengina, Natalia, Mitin, Timur

“…Background To our knowledge, there is no clinical data pertaining to COVID-19 outcomes and safety of COVID-19 vaccination in Russian patients with…”
Get full text

Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise by Mitin, Timur, Dengina, Natalia, Chernykh, Marina, Usychkin, Sergey, Gladkov, Oleg, Degnin, Catherine, Chen, Yiyi, Nosov, Dmitry, Tsimafeyeu, Ilya, Thomas, Charles R., Tjulandin, Sergei

“…Trimodality bladder preservation (BP) is an accepted alternative to radical cystectomy for patients with muscle invasive bladder cancer (MIBC). The global…”
Get full text

Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise by Mitin, Timur, Degnin, Catherine, Chen, Yiyi, Shirvani, Shervin, Gillespie, Erin, Hoffe, Sarah, Latifi, Kujtim, Nabavizadeh, Nima, Dengina, Natalia, Chernich, Marina, Usychkin, Sergey, Kharitonova, Ekaterina, Egorova, Yulia, Pankratov, Alexandr, Tsimafeyeu, Ilya, Thomas, Charles R., Tjulandin, Sergei, Likhacheva, Anna

“…Radiation therapy (RT) is an effective treatment modality for hepatocellular carcinoma (HCC), but globally, it is underutilized. In Russia, practice patterns…”
Get full text

Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma by Tsimafeyeu, Ilya V, Demidov, Lev V, Madzhuga, Albina V, Somonova, Oksana V, Yelizarova, Anna L

“…In experimental systems, interference with coagulation can affect tumor biology. We suggested that abnormal coagulation could be a negative predictor for…”
Get full text

Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry by Tsimafeyeu, Ilya, Shatkovskaya, Oxana, Krasny, Sergei, Nurgaliev, Nurzhan, Varlamov, Ilya, Petkau, Vladislav, Safina, Sufia, Zukov, Ruslan, Mazhbich, Mikhail, Statsenko, Galina, Varlamov, Sergey, Novikova, Olga, Zaitsev, Igor, Moiseyev, Pavel, Rolevich, Alexander, Evmenenko, Alesya, Popova, Irina, Kaidarova, Dilyara, Vladimirova, Liubov

“…Background Real‐world data describing outcomes of treatment among metastatic renal cell carcinoma (mRCC) patients are limited and heterogeneous. Aim RENSUR3…”
Get full text

Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer by Imyanitov, Evgeny N., Demidova, Irina A., Gordiev, Marat G., Filipenko, Maxim L., Kekeyeva, Tatyana V., Moliaka, Yuri K., Gervas, Polina A., Kozhemyako, Valeriy B., Vodolazhskiy, Dmitriy I., Sergeyeva, Liubov A., Fattakhova, Dinara U., Iyevleva, Aglaya G., Mitiushkina, Natalia V., Kuligina, Ekatherina Sh, Barinov, Alexey A., Mommaeva, Meriiam S., Aleksakhina, Svetlana N., Tsimafeyeu, Ilya V., Tjulandin, Sergey A.

“…Introduction This study was aimed to evaluate distribution of epidermal growth factor receptor (EGFR) mutations in a large series of Russian lung cancer (LC)…”
Get full text

The future landscape of cancer incidence and mortality until 2036 in the Russian Federation by Tsimafeyeu, Ilya, Rahib, Lola

“…e22518 Background: Understanding the future of the burden of cancer is important to plan for future research funding, allocations of resources and other…”
Get full text

Molecular Modeling, de novo Design and Synthesis of a Novel, Extracellular Binding Fibroblast Growth Factor Receptor 2 Inhibitor Alofanib (RPT835) by Tsimafeyeu, Ilya, Daeyaert, Frits, Joos, Jean-Baptiste, Aken, Koen V, Ludes-Meyers, John, Byakhov, Mikhail, Tjulandin, Sergei

“…Fibroblast growth factor (FGF) receptors (FGFRs) play a key role in tumor growth and angiogenesis. The present report describes our search for an…”
Get more information

Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma by Tsimafeyeu, Ilya

“…On November 23, 2015, the US Food and Drug Administration (FDA) approved nivolumab for the treatment of metastatic renal cell carcinoma (RCC), thus opening a…”
Get full text

Lenvatinib and pembrolizumab in patients with metastatic papillary renal cell carcinoma: A phase 2 pilot study by Tsimafeyeu, Ilya, Sultanbaev, Alexander, Vilkov, Sergey

“…109 Background: Traditionally, metastatic papillary renal cell carcinoma (papillary mRCC) has been treated with tyrosine kinase inhibitors, resulting in a 23%…”
Get full text

First‐line checkpoint inhibitors in PD‐L1‐positive patients with advanced urothelial carcinoma by Tsimafeyeu, Ilya, Tjulandin, Sergei

Get full text